Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis

BACKGROUND: BRAF gene mutation causes melanoma patients to develop drug resistance after 8–9 months BRAF inhibitors treatment. Therefore, overcoming BRAF inhibitor resistance has important implications for improving patient survival. Sorafenib directly inhibits tumor cell proliferation by blocking t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Fengjie, Li, Shiyan, Liu, Daisong, Chen, Jian, Han, Chaofei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798636/
https://www.ncbi.nlm.nih.gov/pubmed/35117506
http://dx.doi.org/10.21037/tcr.2020.01.62

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798636/
https://www.ncbi.nlm.nih.gov/pubmed/35117506
http://dx.doi.org/10.21037/tcr.2020.01.62

Ejemplares similares